Zollinger‑Ellison syndrome (gastrinoma) – hereditary form - Symptoms, Causes, Treatment & Prevention

```html

Overview

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach to secrete large amounts of acid, leading to severe peptic ulcers, diarrhea, and malabsorption. While most cases are sporadic, approximately 20‑25 % are hereditary and occur as part of the multiple endocrine neoplasia type 1 (MEN 1) syndrome.

Who it affects: ZES can occur at any age but hereditary cases usually present in the 3<sup>rd</sup>–4<sup>th</sup> decade. Both men and women are affected equally. Because MEN 1 is autosomal‑dominant, each child of an affected individual has a 50 % chance of inheriting the mutation.

Prevalence: Overall, ZES occurs in about 1–3 people per million per year (Mayo Clinic, 2021). Hereditary ZES accounts for roughly 0.2–0.6 cases per million, making it an exceptionally uncommon condition.

Symptoms

Symptoms result from hyperacidic gastric secretions and from the tumor itself. They can vary widely, which often delays diagnosis.

Gastro‑intestinal symptoms

• Recurrent, painful peptic ulcers: often multiple, located beyond the duodenum (e.g., jejunal ulcers) and resistant to standard ulcer therapy.
• Abdominal pain: crampy or burning pain that may improve after eating (duodenal ulcer pattern) or worsen (gastric ulcer pattern).
• Diarrhea: watery, sometimes fatty (steatorrhea) due to rapid intestinal transit and bile‑acid malabsorption.
• Malabsorption & weight loss: loss of fat‑soluble vitamins (A, D, E, K) and protein‑calorie malnutrition.
• Nausea & vomiting: may occur with high gastric volume.

Systemic / tumor‑related symptoms

• Gastroparesis: delayed stomach emptying from chronic acid injury.
• Gastro‑esophageal reflux disease (GERD): heartburn and regurgitation.
• Gastric outlet obstruction: large ulcers can cause narrowing of the pylorus.
• Signs of MEN 1: hyperparathyroidism (kidney stones, bone pain), pituitary tumors (headaches, visual changes), or other pancreatic neuroendocrine tumors.

Red‑flag symptoms that warrant immediate evaluation

• Profuse, unexplained gastrointestinal bleeding (hematemesis or melena).
• Sudden severe abdominal pain with a rigid abdomen (possible perforated ulcer).
• Persistent vomiting with inability to keep fluids down, leading to dehydration.
• Rapid, unexplained weight loss (>10 % body weight in 6 months).

Causes and Risk Factors

The hereditary form of ZES is most often linked to germline mutations in the MEN1 gene located on chromosome 11q13. MEN1 encodes menin, a tumor‑suppressor protein that regulates cell growth in endocrine tissues. Loss‑of‑function mutations lead to unchecked proliferation of gastrin‑producing cells.

Key risk factors

• Family history of MEN 1: first‑degree relatives with confirmed MEN1 mutations or clinical MEN 1 features.
• Known MEN1 gene mutation: identified through genetic testing even before symptom onset.
• Age: hereditary ZES typically manifests between ages 20–45, but penetrance can be as early as the teenage years.
• Other endocrine neoplasias: hyperparathyroidism or pituitary adenoma increases suspicion for MEN 1‑related ZES.

Diagnosis

Diagnosing hereditary ZES requires a combination of biochemical testing, imaging, and genetic evaluation.

Biochemical tests

• Fasting serum gastrin level: markedly elevated (>1,000 pg/mL) is highly suggestive. Levels >10× upper limit of normal, especially with low gastric pH, are diagnostic (CDC, 2023).
• Secretin stimulation test: intravenous secretin paradoxically raises gastrin in ZES, confirming hypersecretion when fasting gastrin is borderline.
• Stool pH & fecal fat: often acidic (pH < 5.5) and increased fat, indicating malabsorption.

Imaging studies

• Contrast‑enhanced CT or MRI of the abdomen: localizes primary gastrinoma and assesses for liver metastases (present in 20‑30 % at diagnosis).
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: highly sensitive for neuroendocrine tumors, including small duodenal lesions.
• Endoscopic ultrasound (EUS): useful for detecting sub‑centimeter tumors in the pancreas or duodenum.

Genetic testing

If a patient has a personal or family history suggestive of MEN 1, sequencing of the MEN1 gene is recommended. Identification of a pathogenic variant confirms hereditary ZES and guides screening of relatives.

Diagnostic criteria (summary)

1. Fasting gastrin >1,000 pg/mL (or >10× ULN) with gastric pH <2, or positive secretin test.
2. Radiologic evidence of a gastrinoma (CT, MRI, EUS, or functional imaging).
3. Presence of a pathogenic MEN1 mutation confirms hereditary form.

Treatment Options

Therapy targets two main problems: excess gastric acid and the gastrinoma itself.

Acid‑suppression (first‑line)

• High‑dose proton pump inhibitors (PPIs): omeprazole 60–80 mg daily, esomeprazole 40 mg daily, or equivalent. PPIs normalize gastric pH, heal ulcers, and control diarrhea in >90 % of patients (Cleveland Clinic, 2022).
• Histamine‑2 receptor antagonists: may be added for breakthrough symptoms, but PPIs remain the cornerstone.

Surgical management

• En‑bloc resection: removal of the gastrinoma(s) with clear margins. Preferred for solitary, well‑localized tumors without metastasis.
• Pancreaticoduodenectomy (Whipple procedure): indicated for larger pancreatic lesions or those involving the duodenum.
• Debulking surgery: for metastatic disease to reduce tumor burden and improve control of hormone secretion.

Medical therapies for tumor control

• Somatostatin analogues (e.g., octreotide, lanreotide): inhibit gastrin release and can shrink metastatic lesions.
• Targeted agents: everolimus (mTOR inhibitor) or sunitinib (tyrosine kinase inhibitor) are FDA‑approved for progressive pancreatic neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive tumors and is effective in metastatic ZES.

Management of MEN 1 manifestations

Because hereditary ZES rarely occurs in isolation, patients often need concurrent treatment for hyperparathyroidism (parathyroidectomy) and pituitary adenomas (surgery, dopamine agonists, or radiotherapy).

Lifestyle and supportive care

• Small, frequent meals low in fat to reduce acid stimulus.
• Avoidance of smoking, alcohol, and NSAIDs (which worsen ulcer disease).
• Calcium and vitamin D supplementation if malabsorption is present.
• Regular bone‑density screening for hyperparathyroidism‑related osteoporosis.

Living with Zollinger‑Ellison syndrome (gastrinoma) – hereditary form

Management is lifelong and multidisciplinary. Below are practical tips for day‑to‑day well‑being.

Medication adherence

• Take PPIs exactly as prescribed; missing doses can cause rebound hyperacidity.
• Set a weekly reminder to refill prescriptions—PPI discontinuation without a doctor’s guidance can precipitate ulcer recurrence.

Nutrition

• Eat 5–6 small meals per day rather than three large ones.
• Choose low‑fat, low‑acidic foods (e.g., oatmeal, bananas, grilled chicken).
• Limit citrus, tomato‑based sauces, chocolate, and caffeine, which stimulate acid.
• If steatorrhea is present, a dietitian may recommend medium‑chain triglyceride (MCT) oil supplements for better fat absorption.

Monitoring

• Serum gastrin and fasting gastric pH every 6–12 months while on therapy.
• Annual abdominal imaging (MRI or CT) to detect new or recurrent tumors.
• Screening for MEN 1 complications: calcium & PTH every 1–2 years, prolactin & IGF‑1 annually, and MRI of the pituitary every 3 years.

Physical activity

Regular moderate exercise (150 min/week) improves gut motility and bone health, but avoid high‑intensity workouts that may exacerbate abdominal pain after meals.

Psychosocial support

Living with a rare hereditary cancer can be stressful. Consider joining patient support groups (e.g., NET Patient Foundation) and counseling services. Genetic counseling is essential for family planning.

Prevention

Because hereditary ZES stems from an inherited gene mutation, primary prevention is not possible. However, the following strategies can mitigate disease burden:

• Genetic counseling and testing: relatives of an affected person should undergo predictive testing. Early identification allows surveillance before symptoms arise.
• Routine surveillance: For mutation carriers, begin annual fasting gastrin measurement and imaging by age 10–12 (per International MEN 1 Consensus, 2021).
• Lifestyle modifications: Avoid smoking and chronic NSAID use, both of which accelerate ulcer formation.
• Vaccinations: Patients on high‑dose PPIs have an increased risk of Clostridioides difficile infection; keep vaccinations up‑to‑date (e.g., C. difficile vaccine if eligible).

Complications

If left untreated or inadequately controlled, ZES can lead to serious health issues:

• Perforated peptic ulcer: life‑threatening intra‑abdominal infection.
• Severe gastrointestinal bleeding: may require urgent endoscopic or surgical intervention.
• Gastric outlet obstruction: chronic vomiting and inability to eat.
• Metastatic disease: liver is the most common site; metastases reduce survival (5‑year survival drops from >80 % for localized disease to 30‑40 % with liver involvement).
• Osteoporosis & nephrolithiasis: from co‑existent hyperparathyroidism.
• Nutritional deficiencies: fat‑soluble vitamin loss can cause bleeding diathesis, night blindness, and neuromuscular weakness.
• Psychological impact: chronic pain and chronic disease burden may lead to anxiety or depression.

When to Seek Emergency Care

---

References: Mayo Clinic. Zollinger‑Ellison Syndrome. 2021; CDC. Diagnostic Testing for Neuroendocrine Tumors. 2023; Cleveland Clinic. Management of Gastrinomas. 2022; NIH Genetic and Rare Diseases Information Center. MEN1. 2024; WHO. Neuroendocrine Tumors Fact Sheet. 2023; International MEN1 Consensus Group. Clinical Guidelines for MEN1. 2021.

```